Merck hep C drug faces delays
The pharma giant's Q4 EPS slid 1% to 87 cents, topping, while revenue fell 7% to $10.48 bil, missing. It guided '15 EPS at $3.32-$3.47, below views. Merck (MRK) also said the FDA plans to revoke the "breakthrough therapy" status for its hepatitis C treatment following recent hep C drug launches from Gilead Sciences (GILD) and AbbVie (ABBV). The designation is meant to speed FDA review, meaning it could take longer for the drug to get to market. Merck shares fell 3.2% to 59.05.
Terms and Privacy Policy